Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

Highlight

• Extended low-intensity apixaban (2.5 mg twice daily) reduces recurrent VTE by 87% versus placebo in patients with provoked VTE and enduring risk factors.
• In cancer-associated VTE, extended reduced-dose apixaban (2.5 mg twice daily) is noninferior to full-dose for preventing recurrent events, with significantly less clinically relevant bleeding.
• Both trials confirm the safety profiles of extended apixaban therapy, with low rates of major bleeding and no excess mortality related to treatment.

Study Background and Disease Burden

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of morbidity and mortality globally. Anticoagulation remains the cornerstone of VTE management. However, determining the optimal duration of anticoagulation therapy, particularly after an initial provoked event in patients with persistent risk factors, remains an area of ongoing clinical uncertainty. Prolonged anticoagulation reduces recurrence risk but increases bleeding complications. This dilemma is accentuated in active cancer patients, who exhibit a hypercoagulable state and are at higher risk for both thrombosis recurrence and bleeding. Novel anticoagulants such as apixaban offer convenience and a favorable safety profile, but evidence is needed regarding their extended use and dosage optimization in these distinct populations.

Study Design

Two recent randomized, double-blind clinical trials funded by the Bristol-Myers Squibb-Pfizer Alliance investigated apixaban for extended anticoagulation in different VTE settings.

The HI-PRO trial enrolled 600 adult patients with VTE provoked by a transient factor (such as surgery, trauma, or immobility) who also had at least one enduring risk factor and had completed 3 months of anticoagulation. Patients were randomized 1:1 to low-dose apixaban (2.5 mg twice daily) or placebo for 12 months. The primary efficacy endpoint was symptomatic recurrent VTE, while safety focused on major bleeding episodes as defined by the International Society on Thrombosis and Hemostasis criteria.

The API-CAT trial included 1766 patients with active cancer and history of proximal DVT or PE who had completed at least 6 months of anticoagulation. They were randomized to receive either reduced-dose (2.5 mg twice daily) or full-dose (5 mg twice daily) apixaban for 12 months. The primary outcome was adjudicated recurrent VTE (fatal or nonfatal), tested for noninferiority. Key secondary outcomes included clinically relevant bleeding events and mortality.

Key Findings

HI-PRO Trial (Provoked VTE with Enduring Risk Factors):
Among 600 patients (mean age 59.5 years, 57% female, 19.2% non-White), recurrent VTE occurred in 1.3% (4/300) of the apixaban group versus 10.0% (30/300) in placebo (hazard ratio [HR] 0.13, 95% confidence interval [CI] 0.04–0.36; P<0.001), demonstrating a substantial 87% risk reduction with low-dose apixaban.

Major bleeding was rare, with only 1 case in the apixaban group and none in the placebo group. Clinically relevant nonmajor bleeding was more frequent with apixaban (4.8% vs 1.7%), though statistically borderline (HR 2.68; 95% CI 0.96–7.43; P=0.06). Mortality was low and unrelated to cardiovascular or hemorrhagic causes.

These results underscore that extended low-intensity apixaban in selected patients effectively prevents symptomatic VTE recurrence with minimal major bleeding risk.

API-CAT Trial (Cancer-Associated VTE):
In 1766 patients (median age not specified, treated a median of 8.0 months after VTE event), recurrent VTE occurred in 2.1% (18/866) of the reduced-dose group and 2.8% (24/900) of the full-dose group. The adjusted subhazard ratio was 0.76 (95% CI 0.41–1.41; P=0.001 for noninferiority), confirming reduced-dose apixaban’s effectiveness is statistically noninferior to full-dose therapy.

Clinically relevant bleeding events were significantly fewer in the reduced-dose arm (12.1% vs 15.6%; adjusted subhazard ratio 0.75; 95% CI 0.58–0.97; P=0.03). Mortality rates were comparable (17.7% vs 19.6%).

These findings advocate for the use of reduced-dose apixaban for extended anticoagulation in active cancer patients to balance thrombosis prevention with bleeding risk.

Expert Commentary

The HI-PRO trial provides critical evidence filling the knowledge gap about extended anticoagulation duration for patients with provoked VTE but persistent risk factors. Historically, the presence of a transient provoking factor prompted short-term anticoagulation (3-6 months) due to lower recurrence risk. However, enduring risk factors elevate this risk, necessitating reconsideration of treatment length. The low-dose apixaban regimen exhibited remarkable efficacy with an excellent safety profile, suggesting that long-term, low-intensity anticoagulation is a viable strategy in this population.

In oncology, the challenge often lies in balancing efficacy and safety. The API-CAT trial’s demonstration that halving apixaban dose after 6 months maintains VTE prevention efficacy while reducing bleeding offers a pragmatic approach. This nuanced dosing strategy aligns well with personalized medicine principles.

Some limitations include the single-center design of HI-PRO, restricted ethnic diversity, and exclusion of patients with ongoing provoking factors. Larger multicenter studies could enhance generalizability. Likewise, long-term outcomes beyond 12 months remain unknown in both trials. Cost-effectiveness analyses would be valuable given extended therapy durations.

Mechanistically, apixaban’s inhibition of factor Xa reduces thrombin generation, helping suppress clot propagation while preserving hemostasis to a degree, which may explain favorable safety. Reduced-dose regimens may optimize this therapeutic window further.

Conclusion

Extended use of low-intensity apixaban (2.5 mg twice daily) significantly reduces recurrent VTE in patients with provoked VTE and enduring risk factors, with minimal major bleeding events, supporting its consideration as standard care in this subgroup. For patients with active cancer-associated VTE, extended reduced-dose apixaban offers noninferior protection against recurrence and reduces bleeding complications compared to full-dose therapy, representing a meaningful step forward in balancing thrombosis and bleeding risks.

Future research should investigate optimal treatment duration beyond 12 months, long-term safety, and applicability across broader populations. Meanwhile, these data support clinical guidelines endorsing tailored extended anticoagulation to improve patient outcomes and safety.

References

• Piazza G, et al. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. N Engl J Med. 2025;393(12):1166-1176. doi:10.1056/NEJMoa2509426
• Mahé I, et al. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2025;392(14):1363-1373. doi:10.1056/NEJMoa2416112
• Kearon C, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline. Chest. 2020;158(3):1143-1163.